Niemann-Pick disease type C is a rare inherited lysosomal storage disorder that affects roughly one in every 150,000 people. In patients with the condition, the body cannot properly process cholesterol and other fats inside cells, so these substances accumulate, particularly in the brain. The result is a progressive neurological decline that erodes movement, coordination and the ability to swallow, and that shortens lives. The disease is autosomal recessive, caused by variants in the NPC1 gene in about 95 percent of cases or in NPC2, and it has no cure.
Patients whose neurological symptoms begin before age 6 have the most serious form, known as infantile-onset NPC. For those families, the treatment landscape has been thin. The FDA approved two therapies in September 2024, arimoclomol, sold as Miplyffa by Zevra Therapeutics, and levacetylleucine, sold as Aqneursa by IntraBio. Both address some symptoms, but neither has been shown to reduce the risk of death, and both carry age and weight restrictions that limit access for the youngest patients. Miglustat, originally developed for Gaucher disease, is widely used off label.
On November 17, 2026, that changed. The US Food and Drug Administration approved Lembaz, also known as adrabetadex, as the first treatment shown to help people with infantile-onset NPC live longer. The agency cleared the drug to reduce the risk of death in adults and pediatric patients weighing at least 7 kg whose neurological symptoms began before age 6. Acting FDA Commissioner Kyle Diamantas called the approval an important milestone. The application was granted to Mandos LLC, a subsidiary of Beren Therapeutics P.B.C.
Lembaz is a cyclodextrin-based therapy given by intrathecal injection into the spinal canal every two weeks. According to Beren, it is the first medicine to address the cholesterol trafficking defect that causes the disease, by re-establishing the movement of cholesterol inside cells so that it reaches the compartments where it is needed. The drug is for intrathecal use only and carries a boxed warning for hearing impairment, including permanent hearing loss.
Key Facts
The FDA announced on November 17, 2026, that its decision rested on an overall survival analysis drawn from 36 patients treated across three clinical studies and an expanded access program, all of whom had neurological manifestations before age 6. Treated patients lived longer than matched external controls, with a 55 percent reduction in the risk of death. Median survival was 8.5 years for treated patients versus 4.9 years for controls. The agency accepted the comparison with matched external controls as the adequate and well-controlled study supporting approval.
The benefit held regardless of whether patients also received miglustat, which is used off label in this population. Beren Therapeutics announced on November 17, 2026, that the approval makes Lembaz the first medicine to improve survival in infantile-onset NPC, and that the company received a Priority Review Voucher. The drug had earlier received Breakthrough Therapy designation.
Safety is a central part of the label. The boxed warning covers hearing impairment, including permanent hearing loss ranging from mild to profound, which occurred in some patients whose hearing was normal before treatment. Baseline testing includes pure tone audiometry, speech recognition and tympanometry, and repeat evaluations guide dosing, with possible dose adjustments. Ataxia and fatigue can also occur in the first days after a dose and have led to hospitalization.
NeurologyLive reported on November 17, 2026, that about 475 US children have infantile-onset NPC, roughly half of all US patients. According to Beren, mean age at death is about 5.6 years when symptoms begin before age 2 and 13.4 years when they begin between ages 2 and 6. On average, patients with NPC live about 13 years, according to the FDA, which estimates that a few hundred people in the United States have the condition.
The two older therapies remain on the market but occupy a different niche. Arimoclomol is approved for patients 2 and older and is used with miglustat, while levacetylleucine is approved for those weighing at least 15 kg. Neither has been shown to reduce mortality, and their restrictions leave the youngest and smallest patients without an option that changes the course of the disease.
Analysis
The most important caveat about this approval is its architecture. Contemporary Pediatrics reported on November 17, 2026, that the evidence rests on external rather than randomized controls, a design that carries an inherent limitation because historical patients may differ from treated patients in ways that matching cannot fully address. An earlier randomized trial failed, and the FDA granted breakthrough designation in 2016 under a previous sponsor, rescinded it after a phase 2b/3 trial lasting 12 months, then granted it again in 2025.
The numbers have also moved. An earlier analysis presented in March 2026 compared 72 treated children with 119 matched controls and reported a 71 percent lower risk of death and five-year survival of 84 percent versus 42 percent. That analysis differs from the one reflected in the approval, which centers on 36 treated patients and a 55 percent reduction in the risk of death. Regulators evidently settled on the more conservative framing, and the fact that the label leans on the smaller, externally controlled dataset is the detail that will draw the closest scrutiny from clinicians and payers.
What this really means is that the approval is best understood as a judgment about direction rather than precision. The effect size is large, the disease is relentlessly fatal, and the agency accepted a control group it does not usually accept, which signals that the unmet need outweighed the methodological discomfort. It does not prove that every child will gain 3.6 years of median survival, and it does not answer the question of how much functional benefit accompanies the survival gain. Those are questions for post marketing data.
The mechanism matters too. If Lembaz genuinely restores intracellular cholesterol trafficking, it is treating the biology rather than the symptoms, which is a different proposition from the two drugs approved in 2024. That distinction is what the company is selling and what families will hear, and it is reasonable, but the survival endpoint, not the mechanism, is what carried the decision.
Why It Matters
For families, the practical significance is that a fatal pediatric disease now has a therapy with a mortality benefit on its label. Heather Moran-Teal of the National Niemann-Pick Disease Foundation said the approval brings a new kind of hope for families. That language is not incidental. Infantile-onset NPC strips away movement, speech and swallowing in early childhood, and until now the treatment conversation was about managing symptoms while the disease progressed.
Timing is the other half of the story. Elizabeth Berry-Kravis of Rush University Medical Center, who was lead investigator for the expanded access program, said that lost neurological function cannot be regained, so early diagnosis and prompt treatment are critical. That reframes the clinical problem as one of detection. A disease affecting about one in 150,000 people will not be on every pediatrician's short list, and a therapy that preserves function only if given early creates pressure to shorten the diagnostic odyssey.
There is also a monitoring burden that comes with the benefit. Every two weeks, an intrathecal injection. Repeated audiology. Attention to ataxia and fatigue after dosing. For a family already managing a neurodegenerative disease, that schedule is a real cost, and the hearing risk means the therapy can take something even as it gives time.
Next Up
Pharmaphorum reported on November 17, 2026, that Lembaz will be available at US treatment sites from early December 2026, and Beren said it will be available at commercial sites nationwide in early December. List pricing has not been announced. The company is standing up a Family Support program offering out of pocket assistance, insurance and logistics navigation, and site identification, along with a Caregiver Ambassador Program.
The near term questions are access and evidence. How quickly centers are certified to administer an intrathecal product every two weeks, whether payers cover it, and whether real world data confirm the survival signal outside a matched comparison will determine how far this approval reaches. For now, the milestone is concrete: the first drug shown to help these patients live longer.
Comments (0)
Log in or sign up to leave a comment.
No comments yet. Be the first to share your thoughts.